StockNote
AMV
Viet My Pharmaceutical Manufacturing and Medical Equipment Joint Stock Company (AMV) was established in 2002. The company's main business is the production and trading of medical equipment and quick diagnostic products. The company was the first domestic enterprise to produce a "quick diagnostic" product line. The company's main products include rapid diagnostic tests for conception, rapid diagnosis of HIV, hepatitis B tablets, tuberculosis, syphilis. In which, rapid diagnostic testing of conception is the main product of the Company and is currently used by many hospitals and medical facilities. Currently, AMVI's factory has an average production line producing about 200,000 products/ month, the productivity of this line can reach 800,000 - 1,000,000 products/ month. Amvi Biotech specializes in the production of high-tech diagnostic parts with the entire line and modern technology transferred from the US. Production capacity: 25 million tests/year. On December 20, 2009, AMV officially traded on the Hanoi Stock Exchange (HNX).
AMV currently has a market capitalization of roughly VND 157 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 15,5x is 2% above its own 7-year average (15,2x), suggesting the stock is trading richer than its historical norm. P/B stands at 0,1x, 82% below its multi-year average of 0,6x. Return on equity (ROE) is at -3,6%, up from -4,4% the year before. Its debt-to-equity ratio of 0x is low, reflecting a conservative capital structure. In 2025, revenue fell 49% year-on-year while after-tax profit fell 470%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.